Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Liraglutide in the context of fat loss, obesity & body recomposition.

The present study was designed to determine: (i) whether an equal degree of weight loss by liraglutide or lifestyle changes has a different impact on MASLD extent and IL-1β expression in peripheral blood mononuclear cells from obese subjects with prediabetes or early T2D; (ii) whether baseline IL-1β levels may predict the extent of weight loss and related metabolic changes.

Why It Was Studied

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major cardiovascular risk (CV) factor.

Interleukin-1β (IL-1β), a cytokine involved in the pathogenesis of obesity-associated inflammation and type 2 diabetes (T2D), promotes hepatic steatosis.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.

How the Study Was Run

The design is described as randomized.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Obesity, Liraglutide, Leukocytes, Mononuclear, Prediabetic State, Interleukin-1beta and Weight Loss.

Author keywords: Adipose tissue, Biomarker, Inflammation, Interleukin-1β, Liver disease and MASLD.

What This Means in Plain Language

The paper is a randomized study of Liraglutide in people with fat loss, obesity & body recomposition.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Cardiovascular diabetology), a journal based in England.

More context: the Liraglutide compound page, Fat loss, obesity & body recomposition research.